Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. (29th December 2015)

• Record Type: Journal Article
• Authors: Wewer Albrechtsen, Nicolai J.; Veedfald, Simon; Plamboeck, Astrid; Deacon, Carolyn F.; Hartmann, Bolette; Knop, Filip K.; Vilsboll, Tina; Holst, Jens J.
• Other Names: Marfella Raffaele Academic Editor.
• Is Part Of: Journal of diabetes research. Volume 2016(2016)
• Publication Date: 2015-12-29
• Subjects: Diabetes -- Periodicals; Diabetes -- Pathophysiology -- Periodicals; Diabetes -- Prevention -- Periodicals; Diabetes -- Etiology -- Periodicals; Diabetes -- Epidemiology -- Periodicals; Diabetes -- Pathogenesis -- Periodicals; 616.462005
• DOI: 10.1155/2016/8352957
• Languages: English
• ISSNs: 2314-6745

Abstract

Abstract : Glucagon levels are increasingly being included as endpoints in clinical study design and more than 400 current diabetes-related clinical trials have glucagon as an outcome measure. The reliability of immune-based technologies used to measure endogenous glucagon concentrations is, therefore, important. We studied the ability of immunoassays based on four different technologies to detect changes in levels of glucagon under conditions where glucagon levels are strongly suppressed. To our surprise, the most advanced technological methods, employing electrochemiluminescence or homogeneous time resolved fluorescence (HTRF) detection, were not capable of detecting the suppression induced by a glucose clamp (6 mmol/L) with or without atropine in five healthy male participants, whereas a radioimmunoassay and a spectrophotometry-based ELISA were. In summary, measurement of glucagon is challenging even when state-of-the-art immune-based technologies are used. Clinical researchers using glucagon as outcome measures may need to reconsider the validity of their chosen glucagon assay. The current study demonstrates that the most advanced approach is not necessarily the best when measuring a low-abundant peptide such as glucagon in humans.